Business Context and Reporting Period
Company: PRO-DEX, INC. (PDEX)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three months ended September 30, 2024 (First Quarter of Fiscal 2025)
Business Overview: Pro-Dex specializes in the design, development, and manufacture of powered rotary drive surgical instruments (drivers and shavers) for orthopedic, thoracic, and maxocranial facial markets. The company also manufactures rotary air motors for industrial applications.
Key Financial Metrics
| Metric (in thousands) | Q1 2025 (Sep 30, 2024) | Q1 2024 (Sep 30, 2023) |
|---|---|---|
| Net Sales | $14,892 | $11,938 |
| Gross Profit | $5,150 | $3,658 |
| Gross Margin | 35% | 31% |
| Operating Income | $3,013 | $1,833 |
| Net Income | $2,466 | $(615) |
| Diluted EPS | $0.75 | $(0.17) |
| Cash from Operations | $1,887 | $392 |
| Cash & Equivalents (End of Period) | $3,081 | $1,904 |
| Total Debt (Notes Payable) | $13,529 | $11,956 |
| Working Capital | $27,217 | $23,143 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 25% ($2.95 million) year-over-year, driven primarily by a 27% increase in medical device sales and a 28% increase in repair revenue.
- Profitability: The company returned to profitability with Net Income of $2.5 million compared to a Net Loss of $0.6 million in the prior year. This turnaround was significantly aided by a $433,000 unrealized gain on investments, reversing a $2.6 million unrealized loss in the prior year.
- Product Mix: Orthopedic sales grew 38% due to shipments of a next-generation handpiece. Conversely, Thoracic sales declined 24%.
- Debt Restructuring: The company entered into a new $5.0 million Term Loan C with Minnesota Bank & Trust (MBT) in July 2024, using proceeds to repay the entire $3.0 million balance on its revolving loan.
- Share Repurchases: The company repurchased 91,976 shares of common stock for approximately $2.3 million during the quarter.
Guidance, Outlook, and Risks
- Backlog: As of September 30, 2024, the company reported a backlog of approximately $56.8 million, with $45.6 million scheduled for delivery in the remainder of Fiscal 2025.
- Outlook: Management expects production shipments of the newest generation orthopedic handpiece to ramp up in the third and fourth quarters of Fiscal 2025. The company anticipates stabilizing manufacturing absorption rates as direct labor costs grow.
- Internal Controls: Management concluded that disclosure controls and procedures were not effective due to a material weakness regarding controls over the existence of inventory. Remediation efforts are underway, including the hiring of a warehouse manager.
- Customer Concentration: The company faces high concentration risk. One customer accounted for 76% of total sales and 75% of accounts receivable in Q1 2025.
- Liquidity: Management believes existing cash, cash equivalents, and accounts receivable are sufficient to meet requirements for the next 12 months, with access to additional credit via the MBT revolver if needed.
Investor Verification Checklist
- Inventory Controls: Verify the progress of remediation for the material weakness regarding inventory existence and valuation.
- Customer Dependency: Assess the risk associated with the top customer representing 76% of revenue and the stability of their supply agreements.
- Investment Volatility: Review the composition of the investment portfolio ($6.2 million total) and the impact of unrealized gains/losses on reported net income.
- Debt Covenants: Confirm continued compliance with debt covenants, particularly given the new Term Loan C structure and interest rate terms tied to SOFR.
- Backlog Realization: Monitor the conversion of the $56.8 million backlog into actual revenue, noting potential variability in order bookings.